JP2017505337A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017505337A5 JP2017505337A5 JP2016563277A JP2016563277A JP2017505337A5 JP 2017505337 A5 JP2017505337 A5 JP 2017505337A5 JP 2016563277 A JP2016563277 A JP 2016563277A JP 2016563277 A JP2016563277 A JP 2016563277A JP 2017505337 A5 JP2017505337 A5 JP 2017505337A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- chronic
- syndrome
- lymphoma
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 150000001875 compounds Chemical class 0.000 claims 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 13
- 230000001684 chronic effect Effects 0.000 claims 11
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000010099 disease Diseases 0.000 claims 9
- 206010025323 Lymphomas Diseases 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 8
- 201000011510 cancer Diseases 0.000 claims 7
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 6
- 229910052736 halogen Inorganic materials 0.000 claims 6
- 150000002367 halogens Chemical class 0.000 claims 6
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000002768 hydroxyalkyl group Chemical group 0.000 claims 6
- 206010020751 Hypersensitivity Diseases 0.000 claims 5
- 201000002481 Myositis Diseases 0.000 claims 5
- 208000026935 allergic disease Diseases 0.000 claims 5
- 229910052739 hydrogen Inorganic materials 0.000 claims 5
- 239000001257 hydrogen Substances 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 4
- 208000015943 Coeliac disease Diseases 0.000 claims 4
- 206010010741 Conjunctivitis Diseases 0.000 claims 4
- 208000004232 Enteritis Diseases 0.000 claims 4
- 201000005569 Gout Diseases 0.000 claims 4
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 4
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 4
- 208000002193 Pain Diseases 0.000 claims 4
- 206010035664 Pneumonia Diseases 0.000 claims 4
- 201000004681 Psoriasis Diseases 0.000 claims 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 125000003545 alkoxy group Chemical group 0.000 claims 4
- 230000001363 autoimmune Effects 0.000 claims 4
- 208000035475 disorder Diseases 0.000 claims 4
- 201000001155 extrinsic allergic alveolitis Diseases 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 208000022098 hypersensitivity pneumonitis Diseases 0.000 claims 4
- 208000027866 inflammatory disease Diseases 0.000 claims 4
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 4
- 208000017169 kidney disease Diseases 0.000 claims 4
- 206010025135 lupus erythematosus Diseases 0.000 claims 4
- 210000002307 prostate Anatomy 0.000 claims 4
- 201000009890 sinusitis Diseases 0.000 claims 4
- 208000011580 syndromic disease Diseases 0.000 claims 4
- 230000009885 systemic effect Effects 0.000 claims 4
- 206010009900 Colitis ulcerative Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 3
- 201000011152 Pemphigus Diseases 0.000 claims 3
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 3
- 206010047115 Vasculitis Diseases 0.000 claims 3
- 239000002253 acid Substances 0.000 claims 3
- 230000007815 allergy Effects 0.000 claims 3
- 206010009887 colitis Diseases 0.000 claims 3
- 125000004438 haloalkoxy group Chemical group 0.000 claims 3
- 125000001188 haloalkyl group Chemical group 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 210000004072 lung Anatomy 0.000 claims 3
- 210000003739 neck Anatomy 0.000 claims 3
- 201000008383 nephritis Diseases 0.000 claims 3
- 125000003226 pyrazolyl group Chemical group 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 210000003491 skin Anatomy 0.000 claims 3
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 3
- 206010056508 Acquired epidermolysis bullosa Diseases 0.000 claims 2
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 2
- 208000026872 Addison Disease Diseases 0.000 claims 2
- 208000003200 Adenoma Diseases 0.000 claims 2
- 206010001233 Adenoma benign Diseases 0.000 claims 2
- 208000022309 Alcoholic Liver disease Diseases 0.000 claims 2
- 206010001889 Alveolitis Diseases 0.000 claims 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims 2
- 208000032467 Aplastic anaemia Diseases 0.000 claims 2
- 206010003011 Appendicitis Diseases 0.000 claims 2
- 206010003591 Ataxia Diseases 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000032568 B-cell prolymphocytic leukaemia Diseases 0.000 claims 2
- 208000009137 Behcet syndrome Diseases 0.000 claims 2
- 208000008439 Biliary Liver Cirrhosis Diseases 0.000 claims 2
- 208000033222 Biliary cirrhosis primary Diseases 0.000 claims 2
- 208000019838 Blood disease Diseases 0.000 claims 2
- 208000020084 Bone disease Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 208000026310 Breast neoplasm Diseases 0.000 claims 2
- 206010006448 Bronchiolitis Diseases 0.000 claims 2
- 208000023611 Burkitt leukaemia Diseases 0.000 claims 2
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 2
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 2
- 208000006029 Cardiomegaly Diseases 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010008909 Chronic Hepatitis Diseases 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 208000011231 Crohn disease Diseases 0.000 claims 2
- 201000003883 Cystic fibrosis Diseases 0.000 claims 2
- 201000004624 Dermatitis Diseases 0.000 claims 2
- 206010012438 Dermatitis atopic Diseases 0.000 claims 2
- 241001317099 Dystaxia Species 0.000 claims 2
- 201000009273 Endometriosis Diseases 0.000 claims 2
- 208000004145 Endometritis Diseases 0.000 claims 2
- 201000011275 Epicondylitis Diseases 0.000 claims 2
- 206010015218 Erythema multiforme Diseases 0.000 claims 2
- 206010016228 Fasciitis Diseases 0.000 claims 2
- 208000001362 Fetal Growth Retardation Diseases 0.000 claims 2
- 206010070531 Foetal growth restriction Diseases 0.000 claims 2
- 208000004463 Follicular Adenocarcinoma Diseases 0.000 claims 2
- 206010061968 Gastric neoplasm Diseases 0.000 claims 2
- 208000007882 Gastritis Diseases 0.000 claims 2
- 208000005577 Gastroenteritis Diseases 0.000 claims 2
- 208000010412 Glaucoma Diseases 0.000 claims 2
- 208000022461 Glomerular disease Diseases 0.000 claims 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims 2
- 206010018634 Gouty Arthritis Diseases 0.000 claims 2
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 2
- 208000015023 Graves' disease Diseases 0.000 claims 2
- 206010019233 Headaches Diseases 0.000 claims 2
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims 2
- 206010019755 Hepatitis chronic active Diseases 0.000 claims 2
- 101000977771 Homo sapiens Interleukin-1 receptor-associated kinase 4 Proteins 0.000 claims 2
- 208000035150 Hypercholesterolemia Diseases 0.000 claims 2
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 2
- 208000010159 IgA glomerulonephritis Diseases 0.000 claims 2
- 208000026350 Inborn Genetic disease Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 102100023533 Interleukin-1 receptor-associated kinase 4 Human genes 0.000 claims 2
- 208000005615 Interstitial Cystitis Diseases 0.000 claims 2
- 201000008197 Laryngitis Diseases 0.000 claims 2
- 206010024238 Leptospirosis Diseases 0.000 claims 2
- 208000004852 Lung Injury Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 206010052178 Lymphocytic lymphoma Diseases 0.000 claims 2
- 201000009906 Meningitis Diseases 0.000 claims 2
- 206010027406 Mesothelioma Diseases 0.000 claims 2
- 208000034578 Multiple myelomas Diseases 0.000 claims 2
- 206010028289 Muscle atrophy Diseases 0.000 claims 2
- 208000003926 Myelitis Diseases 0.000 claims 2
- 208000009525 Myocarditis Diseases 0.000 claims 2
- 206010029164 Nephrotic syndrome Diseases 0.000 claims 2
- 206010029260 Neuroblastoma Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 208000010191 Osteitis Deformans Diseases 0.000 claims 2
- 208000005141 Otitis Diseases 0.000 claims 2
- 208000027868 Paget disease Diseases 0.000 claims 2
- 206010033645 Pancreatitis Diseases 0.000 claims 2
- 206010034277 Pemphigoid Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 201000007100 Pharyngitis Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 208000007452 Plasmacytoma Diseases 0.000 claims 2
- 206010035742 Pneumonitis Diseases 0.000 claims 2
- 206010065159 Polychondritis Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000012654 Primary biliary cholangitis Diseases 0.000 claims 2
- 206010036790 Productive cough Diseases 0.000 claims 2
- 208000035416 Prolymphocytic B-Cell Leukemia Diseases 0.000 claims 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 2
- 206010037596 Pyelonephritis Diseases 0.000 claims 2
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims 2
- 206010039491 Sarcoma Diseases 0.000 claims 2
- 206010039710 Scleroderma Diseases 0.000 claims 2
- 201000010208 Seminoma Diseases 0.000 claims 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 2
- 206010042033 Stevens-Johnson syndrome Diseases 0.000 claims 2
- 231100000168 Stevens-Johnson syndrome Toxicity 0.000 claims 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims 2
- 208000000491 Tendinopathy Diseases 0.000 claims 2
- 206010043255 Tendonitis Diseases 0.000 claims 2
- 108090000190 Thrombin Proteins 0.000 claims 2
- 208000033781 Thyroid carcinoma Diseases 0.000 claims 2
- 208000024770 Thyroid neoplasm Diseases 0.000 claims 2
- 206010052779 Transplant rejections Diseases 0.000 claims 2
- 206010069363 Traumatic lung injury Diseases 0.000 claims 2
- 208000024780 Urticaria Diseases 0.000 claims 2
- 208000006374 Uterine Cervicitis Diseases 0.000 claims 2
- 206010046851 Uveitis Diseases 0.000 claims 2
- 206010047642 Vitiligo Diseases 0.000 claims 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims 2
- 230000001154 acute effect Effects 0.000 claims 2
- 206010069351 acute lung injury Diseases 0.000 claims 2
- 208000009956 adenocarcinoma Diseases 0.000 claims 2
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 2
- 201000010105 allergic rhinitis Diseases 0.000 claims 2
- 208000004631 alopecia areata Diseases 0.000 claims 2
- 230000036783 anaphylactic response Effects 0.000 claims 2
- 208000003455 anaphylaxis Diseases 0.000 claims 2
- 208000007502 anemia Diseases 0.000 claims 2
- 208000006673 asthma Diseases 0.000 claims 2
- 201000008937 atopic dermatitis Diseases 0.000 claims 2
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 2
- 125000002393 azetidinyl group Chemical group 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 201000004571 bone carcinoma Diseases 0.000 claims 2
- 210000004556 brain Anatomy 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 206010006451 bronchitis Diseases 0.000 claims 2
- 208000000594 bullous pemphigoid Diseases 0.000 claims 2
- 230000001925 catabolic effect Effects 0.000 claims 2
- 230000030833 cell death Effects 0.000 claims 2
- 206010008323 cervicitis Diseases 0.000 claims 2
- 208000003167 cholangitis Diseases 0.000 claims 2
- 201000001352 cholecystitis Diseases 0.000 claims 2
- 208000019069 chronic childhood arthritis Diseases 0.000 claims 2
- 208000025302 chronic primary adrenal insufficiency Diseases 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- 201000001981 dermatomyositis Diseases 0.000 claims 2
- 230000001066 destructive effect Effects 0.000 claims 2
- 208000007784 diverticulitis Diseases 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 208000019258 ear infection Diseases 0.000 claims 2
- 210000003981 ectoderm Anatomy 0.000 claims 2
- 206010014599 encephalitis Diseases 0.000 claims 2
- 206010014665 endocarditis Diseases 0.000 claims 2
- 230000002124 endocrine Effects 0.000 claims 2
- 201000011114 epidermolysis bullosa acquisita Diseases 0.000 claims 2
- 210000000918 epididymis Anatomy 0.000 claims 2
- 201000010063 epididymitis Diseases 0.000 claims 2
- 210000003743 erythrocyte Anatomy 0.000 claims 2
- 208000030533 eye disease Diseases 0.000 claims 2
- 208000030941 fetal growth restriction Diseases 0.000 claims 2
- 125000002541 furyl group Chemical group 0.000 claims 2
- 208000016361 genetic disease Diseases 0.000 claims 2
- 208000005017 glioblastoma Diseases 0.000 claims 2
- 231100000852 glomerular disease Toxicity 0.000 claims 2
- 231100000869 headache Toxicity 0.000 claims 2
- 208000019622 heart disease Diseases 0.000 claims 2
- 208000014951 hematologic disease Diseases 0.000 claims 2
- 208000018706 hematopoietic system disease Diseases 0.000 claims 2
- 208000007475 hemolytic anemia Diseases 0.000 claims 2
- 208000006454 hepatitis Diseases 0.000 claims 2
- 231100000283 hepatitis Toxicity 0.000 claims 2
- 208000025070 hereditary periodic fever syndrome Diseases 0.000 claims 2
- 125000000623 heterocyclic group Chemical group 0.000 claims 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 2
- 229940088597 hormone Drugs 0.000 claims 2
- 239000005556 hormone Substances 0.000 claims 2
- 210000004276 hyalin Anatomy 0.000 claims 2
- 230000009610 hypersensitivity Effects 0.000 claims 2
- 208000016036 idiopathic nephrotic syndrome Diseases 0.000 claims 2
- 125000002883 imidazolyl group Chemical group 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 208000033065 inborn errors of immunity Diseases 0.000 claims 2
- 201000008319 inclusion body myositis Diseases 0.000 claims 2
- 208000026876 intravascular large B-cell lymphoma Diseases 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 125000001786 isothiazolyl group Chemical group 0.000 claims 2
- 206010023332 keratitis Diseases 0.000 claims 2
- 201000010666 keratoconjunctivitis Diseases 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 208000003849 large cell carcinoma Diseases 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 201000011486 lichen planus Diseases 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 208000019423 liver disease Diseases 0.000 claims 2
- 231100000515 lung injury Toxicity 0.000 claims 2
- 230000001926 lymphatic effect Effects 0.000 claims 2
- 201000000564 macroglobulinemia Diseases 0.000 claims 2
- 208000027202 mammary Paget disease Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000004396 mastitis Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 208000030159 metabolic disease Diseases 0.000 claims 2
- 125000002757 morpholinyl group Chemical group 0.000 claims 2
- 201000006417 multiple sclerosis Diseases 0.000 claims 2
- 201000000585 muscular atrophy Diseases 0.000 claims 2
- 206010028417 myasthenia gravis Diseases 0.000 claims 2
- 230000009826 neoplastic cell growth Effects 0.000 claims 2
- 208000009928 nephrosis Diseases 0.000 claims 2
- 231100001027 nephrosis Toxicity 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 201000008482 osteoarthritis Diseases 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 125000001715 oxadiazolyl group Chemical group 0.000 claims 2
- 125000002971 oxazolyl group Chemical group 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 201000010198 papillary carcinoma Diseases 0.000 claims 2
- 201000001976 pemphigus vulgaris Diseases 0.000 claims 2
- 208000008494 pericarditis Diseases 0.000 claims 2
- 230000000737 periodic effect Effects 0.000 claims 2
- 201000001245 periodontitis Diseases 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- 206010034674 peritonitis Diseases 0.000 claims 2
- 208000001297 phlebitis Diseases 0.000 claims 2
- 125000004193 piperazinyl group Chemical group 0.000 claims 2
- 125000003386 piperidinyl group Chemical group 0.000 claims 2
- 210000004180 plasmocyte Anatomy 0.000 claims 2
- 208000008423 pleurisy Diseases 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000028529 primary immunodeficiency disease Diseases 0.000 claims 2
- 201000007094 prostatitis Diseases 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- 208000002815 pulmonary hypertension Diseases 0.000 claims 2
- 125000003373 pyrazinyl group Chemical group 0.000 claims 2
- 125000002098 pyridazinyl group Chemical group 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 2
- 206010039083 rhinitis Diseases 0.000 claims 2
- 201000000306 sarcoidosis Diseases 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 201000000849 skin cancer Diseases 0.000 claims 2
- 201000008261 skin carcinoma Diseases 0.000 claims 2
- 210000000952 spleen Anatomy 0.000 claims 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 claims 2
- 210000003802 sputum Anatomy 0.000 claims 2
- 208000024794 sputum Diseases 0.000 claims 2
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 208000003265 stomatitis Diseases 0.000 claims 2
- 201000004595 synovitis Diseases 0.000 claims 2
- 201000004415 tendinitis Diseases 0.000 claims 2
- 210000001550 testis Anatomy 0.000 claims 2
- 125000003831 tetrazolyl group Chemical group 0.000 claims 2
- 125000001113 thiadiazolyl group Chemical group 0.000 claims 2
- 125000000335 thiazolyl group Chemical group 0.000 claims 2
- 229960004072 thrombin Drugs 0.000 claims 2
- 201000002510 thyroid cancer Diseases 0.000 claims 2
- 208000013077 thyroid gland carcinoma Diseases 0.000 claims 2
- 208000030901 thyroid gland follicular carcinoma Diseases 0.000 claims 2
- 206010044008 tonsillitis Diseases 0.000 claims 2
- 125000001425 triazolyl group Chemical group 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 210000003932 urinary bladder Anatomy 0.000 claims 2
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 1
- 125000005940 1,4-dioxanyl group Chemical group 0.000 claims 1
- 208000023328 Basedow disease Diseases 0.000 claims 1
- 206010005149 Blepharitis allergic Diseases 0.000 claims 1
- 206010006811 Bursitis Diseases 0.000 claims 1
- 201000009030 Carcinoma Diseases 0.000 claims 1
- 208000002177 Cataract Diseases 0.000 claims 1
- 206010057254 Connective tissue inflammation Diseases 0.000 claims 1
- 206010012468 Dermatitis herpetiformis Diseases 0.000 claims 1
- 206010058314 Dysplasia Diseases 0.000 claims 1
- 208000001640 Fibromyalgia Diseases 0.000 claims 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims 1
- 208000003807 Graves Disease Diseases 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 206010023347 Keratoacanthoma Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 102100022691 NACHT, LRR and PYD domains-containing protein 3 Human genes 0.000 claims 1
- 101710126825 NACHT, LRR and PYD domains-containing protein 3 Proteins 0.000 claims 1
- 206010031149 Osteitis Diseases 0.000 claims 1
- 206010031252 Osteomyelitis Diseases 0.000 claims 1
- 206010034038 Parotitis Diseases 0.000 claims 1
- 208000027086 Pemphigus foliaceus Diseases 0.000 claims 1
- 206010036774 Proctitis Diseases 0.000 claims 1
- 208000007893 Salpingitis Diseases 0.000 claims 1
- 201000002661 Spondylitis Diseases 0.000 claims 1
- 208000024799 Thyroid disease Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 claims 1
- 125000002252 acyl group Chemical group 0.000 claims 1
- 125000004103 aminoalkyl group Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 125000003725 azepanyl group Chemical group 0.000 claims 1
- 208000010217 blepharitis Diseases 0.000 claims 1
- 208000018339 bone inflammation disease Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 claims 1
- 208000016532 chronic granulomatous disease Diseases 0.000 claims 1
- 208000018261 cutaneous leukocytoclastic angiitis Diseases 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims 1
- 201000003146 cystitis Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 208000010227 enterocolitis Diseases 0.000 claims 1
- 210000003979 eosinophil Anatomy 0.000 claims 1
- 230000002327 eosinophilic effect Effects 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 238000005469 granulation Methods 0.000 claims 1
- 230000003179 granulation Effects 0.000 claims 1
- 210000003128 head Anatomy 0.000 claims 1
- 208000014829 head and neck neoplasm Diseases 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 125000002632 imidazolidinyl group Chemical group 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 230000000968 intestinal effect Effects 0.000 claims 1
- 210000004561 lacrimal apparatus Anatomy 0.000 claims 1
- 201000003265 lymphadenitis Diseases 0.000 claims 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 1
- 201000005737 orchitis Diseases 0.000 claims 1
- 125000000160 oxazolidinyl group Chemical group 0.000 claims 1
- 125000003566 oxetanyl group Chemical group 0.000 claims 1
- 206010057056 paraneoplastic pemphigus Diseases 0.000 claims 1
- 210000003681 parotid gland Anatomy 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 208000005987 polymyositis Diseases 0.000 claims 1
- 125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 claims 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 claims 1
- 125000001725 pyrenyl group Chemical group 0.000 claims 1
- 125000000168 pyrrolyl group Chemical group 0.000 claims 1
- -1 pyrylyl Chemical group 0.000 claims 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 1
- 125000001984 thiazolidinyl group Chemical group 0.000 claims 1
- 125000001544 thienyl group Chemical group 0.000 claims 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 claims 1
- 208000021510 thyroid gland disease Diseases 0.000 claims 1
- 206010043778 thyroiditis Diseases 0.000 claims 1
- 210000003905 vulva Anatomy 0.000 claims 1
- 208000002003 vulvitis Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN146/CHE/2014 | 2014-01-10 | ||
| IN146CH2014 | 2014-01-10 | ||
| IN3018/CHE/2014 | 2014-06-20 | ||
| IN3018CH2014 | 2014-06-20 | ||
| PCT/IB2015/050119 WO2015104662A1 (en) | 2014-01-10 | 2015-01-07 | Indazole compounds as irak4 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017505337A JP2017505337A (ja) | 2017-02-16 |
| JP2017505337A5 true JP2017505337A5 (https=) | 2018-02-15 |
Family
ID=52462359
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016563277A Ceased JP2017505337A (ja) | 2014-01-10 | 2015-01-07 | Ｉｒａｋ４阻害剤としてのインダゾール化合物 |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US10160753B2 (https=) |
| EP (1) | EP3092226B1 (https=) |
| JP (1) | JP2017505337A (https=) |
| KR (1) | KR20160115933A (https=) |
| CN (1) | CN106458982A (https=) |
| AU (1) | AU2015205348A1 (https=) |
| BR (1) | BR112016015983A2 (https=) |
| CA (1) | CA2935880A1 (https=) |
| CU (1) | CU20160109A7 (https=) |
| EA (1) | EA201691401A1 (https=) |
| HK (1) | HK1231480A1 (https=) |
| IL (1) | IL246555A0 (https=) |
| MX (1) | MX2016009011A (https=) |
| PH (1) | PH12016501338A1 (https=) |
| SG (1) | SG11201605408RA (https=) |
| WO (1) | WO2015104662A1 (https=) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201311888D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compounds |
| GB201311891D0 (en) | 2013-07-03 | 2013-08-14 | Glaxosmithkline Ip Dev Ltd | Novel compound |
| SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| FI3805233T3 (fi) | 2014-01-13 | 2024-04-17 | Aurigene Oncology Ltd | N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon |
| US20180228907A1 (en) | 2014-04-14 | 2018-08-16 | Arvinas, Inc. | Cereblon ligands and bifunctional compounds comprising the same |
| JP2017518348A (ja) * | 2014-06-20 | 2017-07-06 | オーリジーン ディスカバリー テクノロジーズ リミテッドＡｕｒｉｇｅｎｅ Ｄｉｓｃｏｖｅｒｙ Ｔｅｃｈｎｏｌｏｇｉｅｓ Ｌｉｍｉｔｅｄ | Ｉｒａｋ４阻害剤としての置換インダゾール化合物 |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| US10336707B2 (en) | 2014-12-16 | 2019-07-02 | Eudendron S.R.L. | Heterocyclic derivatives modulating activity of certain protein kinases |
| EP3195865A1 (de) | 2016-01-25 | 2017-07-26 | Bayer Pharma Aktiengesellschaft | Kombinationen von irak4 inhibitoren und btk inhibitoren |
| UY36660A (es) | 2015-04-30 | 2016-11-30 | Bayer Pharma AG | Combinaciones de inhibidores de irak4 |
| BR112018000624A2 (pt) * | 2015-07-15 | 2018-09-18 | Aurigene Discovery Technologies Limited | compostos de indazol e azaindazol como inibidores de irak-4 |
| JP6994454B2 (ja) | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
| ES2745284T3 (es) * | 2015-09-11 | 2020-02-28 | Boehringer Ingelheim Int | Heteroarilos sustituidos con pirazolilo y su uso como medicamentos |
| WO2017108744A1 (de) * | 2015-12-22 | 2017-06-29 | Bayer Pharma Aktiengesellschaft | Neue substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| EP3423446B1 (de) | 2016-03-03 | 2020-09-16 | Bayer Pharma Aktiengesellschaft | Neue 2-substituierte indazole, verfahren zu ihrer herstellung, pharmazeutische präparate die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| UA123169C2 (uk) * | 2016-04-29 | 2021-02-24 | Байєр Фарма Акцієнгезелльшафт | Поліморфна форма n-{6-(2-гідроксипропан-2-іл)-2-[2-(метилсульфоніл)етил]-2н-індазол-5-іл}-6-(трифторметил)піридин-2-карбоксаміду |
| KR102409105B1 (ko) * | 2016-04-29 | 2022-06-16 | 바이엘 파마 악티엔게젤샤프트 | 인다졸의 합성 |
| WO2017207385A1 (de) | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Substituierte 3-methylindazole, verfahren zu ihrer herstellung, pharmazeutische präparate, die diese enthalten, sowie deren verwendung zur herstellung von arzneimitteln |
| SG10202011653WA (en) | 2016-06-01 | 2020-12-30 | Bayer Pharma AG | Use of 2-substituted indazoles for the treatment and prophylaxis of autoimmune diseases |
| MY199070A (en) * | 2016-06-01 | 2023-10-12 | Bayer Pharma AG | Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseaes in animals |
| US11254667B2 (en) | 2016-08-17 | 2022-02-22 | Children's Hospital Medical Center | Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors |
| US11542261B2 (en) | 2016-08-17 | 2023-01-03 | Children's Hospital Medical Center | Substituted Imidazo[1,2-a]-pyridines as IRAK 1/4 and FLT3 inhibitors |
| WO2018049214A1 (en) | 2016-09-09 | 2018-03-15 | Incyte Corporation | Pyrazolopyridine derivatives as hpk1 modulators and uses thereof for the treatment of cancer |
| TW201811799A (zh) | 2016-09-09 | 2018-04-01 | 美商英塞特公司 | 吡唑并嘧啶化合物及其用途 |
| UA125650C2 (uk) | 2016-09-09 | 2022-05-11 | Інсайт Корпорейшн | Регулятори нрk1 на основі похідних піразолопіридину та їх застосування для лікування раку |
| US10280164B2 (en) | 2016-09-09 | 2019-05-07 | Incyte Corporation | Pyrazolopyridone compounds and uses thereof |
| US20180228786A1 (en) | 2017-02-15 | 2018-08-16 | Incyte Corporation | Pyrazolopyridine compounds and uses thereof |
| TW202340194A (zh) | 2017-02-16 | 2023-10-16 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
| DK3600270T3 (da) | 2017-03-31 | 2023-07-10 | Aurigene Oncology Ltd | Forbindelser og sammensætninger til behandling af hæmatologiske lidelser |
| US10722495B2 (en) | 2017-09-08 | 2020-07-28 | Incyte Corporation | Cyanoindazole compounds and uses thereof |
| WO2019060693A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc. | CRBN LIGANDS AND USES THEREOF |
| MX2020003190A (es) | 2017-09-22 | 2020-11-11 | Kymera Therapeutics Inc | Degradadores de proteinas y usos de los mismos. |
| US11161854B2 (en) | 2017-10-11 | 2021-11-02 | Merck Sharp & Dohme Corp. | Indazolyl-spiro[2.2]pentane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
| US11174248B2 (en) | 2017-10-11 | 2021-11-16 | Merck Sharp & Dohme Corp. | Indazolyl-spiro[2.3]hexane-carbonitrile derivatives as LRRK2 inhibitors, pharmaceutical compositions, and uses thereof |
| CA3079628A1 (en) * | 2017-10-31 | 2019-05-09 | Curis, Inc. | Compounds and compositions for treating hematological disorders |
| US11065231B2 (en) | 2017-11-17 | 2021-07-20 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides |
| WO2019111218A1 (en) | 2017-12-08 | 2019-06-13 | Cadila Healthcare Limited | Novel heterocyclic compounds as irak4 inhibitors |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| WO2019160915A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| US10745388B2 (en) | 2018-02-20 | 2020-08-18 | Incyte Corporation | Indazole compounds and uses thereof |
| WO2019164847A1 (en) | 2018-02-20 | 2019-08-29 | Incyte Corporation | Indazole compounds and uses thereof |
| US10800761B2 (en) | 2018-02-20 | 2020-10-13 | Incyte Corporation | Carboxamide compounds and uses thereof |
| US11299473B2 (en) | 2018-04-13 | 2022-04-12 | Incyte Corporation | Benzimidazole and indole compounds and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| US11292792B2 (en) | 2018-07-06 | 2022-04-05 | Kymera Therapeutics, Inc. | Tricyclic CRBN ligands and uses thereof |
| TWI842978B (zh) | 2018-07-13 | 2024-05-21 | 美商基利科學股份有限公司 | 衍生物 |
| US10899755B2 (en) | 2018-08-08 | 2021-01-26 | Incyte Corporation | Benzothiazole compounds and uses thereof |
| WO2020035019A1 (zh) * | 2018-08-17 | 2020-02-20 | 浙江海正药业股份有限公司 | 吲唑胺类衍生物及其制备方法和其在医药上的用途 |
| ES2973117T3 (es) | 2018-09-25 | 2024-06-18 | Incyte Corp | Compuestos de pirazolo[4,3-d]pirimidina como moduladores de ALK2 y/o FGFR |
| JP7623943B2 (ja) | 2018-11-30 | 2025-01-29 | カイメラ セラピューティクス， インコーポレイテッド | Ｉｒａｋ分解剤およびそれらの使用 |
| EP3889150A4 (en) * | 2018-12-25 | 2022-02-23 | Shanghai Meiyue Biotech Development Co., Ltd. | COMPOUND SERVING AS IRAQ INHIBITOR |
| GB201904375D0 (en) * | 2019-03-29 | 2019-05-15 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory disorders |
| WO2020259626A1 (zh) * | 2019-06-26 | 2020-12-30 | 南京明德新药研发有限公司 | 作为irak4抑制剂的咪唑并吡啶类化合物 |
| BR112021026517A2 (pt) | 2019-06-28 | 2022-05-10 | Kymera Therapeutics Inc | Degradadores de irak e usos dos mesmos |
| WO2021004533A1 (zh) * | 2019-07-10 | 2021-01-14 | 南京明德新药研发有限公司 | 作为irak4和btk多靶点抑制剂的噁唑类化合物 |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2022001562A (es) | 2019-08-06 | 2022-04-26 | Incyte Corp | Formas solidas de un inhibidor de la cinasa 1 del progenitor hematopoyetico (hpk1). |
| WO2021047677A1 (zh) * | 2019-09-12 | 2021-03-18 | 中国科学院上海药物研究所 | 一类irak4激酶抑制剂及其制备和应用 |
| KR102782229B1 (ko) | 2019-10-02 | 2025-03-20 | (주)카이노스메드 | N-(1h-이미다졸-2-일)벤즈아미드 화합물 및 활성 성분으로 이를 포함하는 약학 조성물 |
| US12551564B2 (en) | 2019-12-10 | 2026-02-17 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021127190A1 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2021127283A2 (en) | 2019-12-17 | 2021-06-24 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| MX2022012135A (es) | 2020-04-04 | 2023-01-18 | Pfizer | Métodos para tratar la enfermedad de coronavirus de 2019. |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11866405B2 (en) | 2020-12-10 | 2024-01-09 | Astrazeneca Ab | Substituted indazoles as IRAK4 inhibitors |
| JP7620711B2 (ja) * | 2020-12-25 | 2025-01-23 | メッドシャイン ディスカバリー インコーポレイテッド | アミドオキサゾール系化合物 |
| PH12023500015A1 (en) | 2020-12-30 | 2024-03-11 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2022174268A1 (en) | 2021-02-15 | 2022-08-18 | Kymera Therapeutics, Inc. | Irak4 degraders and uses thereof |
| KR20240004476A (ko) | 2021-04-08 | 2024-01-11 | 쿠리스 인코퍼레이션 | 암 치료를 위한 병용 요법 |
| AU2022271290A1 (en) | 2021-05-07 | 2023-11-23 | Kymera Therapeutics, Inc. | Cdk2 degraders and uses thereof |
| US12187744B2 (en) | 2021-10-29 | 2025-01-07 | Kymera Therapeutics, Inc. | IRAK4 degraders and synthesis thereof |
| WO2023088435A1 (zh) * | 2021-11-19 | 2023-05-25 | 成都奥睿药业有限公司 | 三取代吡啶衍生物的制备及作为芳香烃受体调节物的应用 |
| EP4434981A4 (en) * | 2021-12-23 | 2025-08-20 | Hangzhou Polymed Biopharmaceuticals Inc | FIVE- AND SIX-MEMBERED COMPOUND, ITS PREPARATION PROCESS AND PHARMACEUTICAL COMPOSITION AND ITS USE |
| EP4472967A4 (en) | 2022-01-31 | 2026-04-15 | Kymera Therapeutics Inc | Iraqi Degradation Agents and Their Uses |
| JP2025513716A (ja) | 2022-03-23 | 2025-04-30 | ライジェル・ファーマシューティカルズ・インコーポレイテッド | Ｉｒａｋ阻害剤としてのピリミド－２－イル－ピラゾール化合物 |
| CN115181066B (zh) * | 2022-06-14 | 2023-07-14 | 浙江宏元药业股份有限公司 | 一种6-氯-2-甲基-2h-吲唑-5-胺的合成方法 |
| TWI896986B (zh) * | 2022-06-15 | 2025-09-11 | 大陸商杭州多域生物技術有限公司 | 一種五元并六元化合物、製備方法、藥物組合物和應用 |
| WO2025003987A1 (ko) * | 2023-06-29 | 2025-01-02 | 동화약품주식회사 | 신규한 카르복사마이드 유도체 화합물 및 이를 포함하는 약학적 조성물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1618092T3 (da) | 2003-05-01 | 2011-01-31 | Bristol Myers Squibb Co | Aryl-substituerede pyrazol-amidforbindelser, der er anvendelige som kinasehæmmere |
| WO2004103954A1 (ja) | 2003-05-20 | 2004-12-02 | Ajinomoto Co., Inc. | アミド誘導体 |
| JP2006526660A (ja) | 2003-06-05 | 2006-11-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | Ｖｒ１レセプターのモジュレーター |
| JP2007525482A (ja) | 2003-10-07 | 2007-09-06 | レノビス， インコーポレイテッド | イオンチャネルリガンドとしてのアミド化合物およびその使用 |
| EP1655297A1 (en) * | 2004-11-03 | 2006-05-10 | Schering Aktiengesellschaft | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| US7906533B2 (en) * | 2004-11-03 | 2011-03-15 | Bayer Schering Pharma Ag | Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors |
| EP1819341A4 (en) | 2004-11-10 | 2011-06-29 | Synta Pharmaceuticals Corp | IL-12 MODULATORY CONNECTIONS |
| CN102633783A (zh) | 2006-02-10 | 2012-08-15 | 转化技术制药公司 | 作为Aurora激酶抑制剂的苯并唑系衍生物、组合物和使用方法 |
| JP5255559B2 (ja) | 2006-03-31 | 2013-08-07 | アボット・ラボラトリーズ | インダゾール化合物 |
| KR20090049076A (ko) | 2006-09-07 | 2009-05-15 | 바이오겐 아이덱 엠에이 인코포레이티드 | 인터루킨-1 수용체-결합 키나제 조절물질로서 인다졸 유도체 |
| CA2663091A1 (en) | 2006-09-07 | 2008-03-13 | Biogen Idec Ma Inc. | Modulators of interleukin-1 receptor-associated kinase |
| KR20090094125A (ko) | 2006-12-08 | 2009-09-03 | 엑셀리시스, 인코포레이티드 | Ｌｘｒ 및 ｆｘｒ 조절자 |
| EP2170834B1 (en) | 2007-07-16 | 2014-01-08 | AbbVie Inc. | Indazoles, benzisoxazoles and benzisothiazoles as inhibitors of protein kinases |
| US20090069288A1 (en) * | 2007-07-16 | 2009-03-12 | Breinlinger Eric C | Novel therapeutic compounds |
| MX2010001446A (es) * | 2007-08-08 | 2010-03-01 | Merck Serono Sa | Derivados de 6-amino-pirimidina-4-carboxamida y compuestos relacionados que se enlazan a los receptores para esfingosina 1-fosfato (s1p) para el tratamiento de esclerosis multiple. |
| CN102281919A (zh) * | 2008-11-19 | 2011-12-14 | 先灵公司 | 二酰基甘油酰基转移酶的抑制剂 |
| EP2379564A1 (en) | 2008-12-19 | 2011-10-26 | Schering Corporation | Bicyclic heterocyclic derivatives and methods of use thereof |
| JP2012254939A (ja) | 2009-10-07 | 2012-12-27 | Astellas Pharma Inc | オキサゾール化合物 |
| US20130053382A1 (en) | 2010-04-30 | 2013-02-28 | Sunil Paliwal | Inhibitors of Phosphoinositide Dependent Kinase 1 (PDK1) |
| JP2011246389A (ja) * | 2010-05-26 | 2011-12-08 | Oncotherapy Science Ltd | Ｔｔｋ阻害作用を有する縮環ピラゾール誘導体 |
| JP5985473B2 (ja) * | 2010-07-13 | 2016-09-06 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | ＩＲＡＫ４モジュレーターとしてのピラゾロ［１，５ａ］ピリミジン及びチエノ［３，２ｂ］ピリミジン誘導体 |
| BR112013015460B1 (pt) * | 2010-12-20 | 2022-01-25 | Merck Serono S.A. | Derivados de indazolil triazol, kit, e composição farmacêutica |
| WO2013042137A1 (en) | 2011-09-19 | 2013-03-28 | Aurigene Discovery Technologies Limited | Bicyclic heterocycles as irak4 inhibitors |
| GB201119401D0 (en) | 2011-11-10 | 2011-12-21 | Ucb Pharma Sa | Therapeutic agents |
| WO2014003483A1 (en) * | 2012-06-29 | 2014-01-03 | Hanmi Pharm. Co., Ltd. | Fused pyrimidine derivatives having inhibitory activity on fms kinases |
| CA2907960C (en) | 2013-05-22 | 2021-10-19 | Children's Hospital Medical Center | Combination therapy for mds |
| TWI667233B (zh) | 2013-12-19 | 2019-08-01 | 德商拜耳製藥公司 | 新穎吲唑羧醯胺，其製備方法、含彼等之醫藥製劑及其製造醫藥之用途 |
| SG11201605408RA (en) | 2014-01-10 | 2016-07-28 | Aurigene Discovery Tech Ltd | Indazole compounds as irak4 inhibitors |
| FI3805233T3 (fi) | 2014-01-13 | 2024-04-17 | Aurigene Oncology Ltd | N-(5-(3-hydroksipyrrolidin-1-yyli)-2-morfolinooksatsolo[4,5-b]pyridin-6-yyli)-2-(2-metylipyridin-4-yyli)okatsoli-karboksamidin (r)- (s)-enantiomeerit irak4-estäjänä syövän hoitoon |
| JO3705B1 (ar) | 2014-11-26 | 2021-01-31 | Bayer Pharma AG | إندازولات مستبدلة جديدة، عمليات لتحضيرها، مستحضرات دوائية تحتوي عليها واستخدامها في إنتاج أدوية |
| JP6994454B2 (ja) | 2015-08-04 | 2022-01-14 | ライジェル ファーマシューティカルズ， インコーポレイテッド | ベンズアゾール化合物ならびに該化合物の作製方法および使用方法 |
-
2015
- 2015-01-07 SG SG11201605408RA patent/SG11201605408RA/en unknown
- 2015-01-07 CN CN201580012991.8A patent/CN106458982A/zh active Pending
- 2015-01-07 KR KR1020167021614A patent/KR20160115933A/ko not_active Withdrawn
- 2015-01-07 US US15/110,309 patent/US10160753B2/en not_active Expired - Fee Related
- 2015-01-07 MX MX2016009011A patent/MX2016009011A/es unknown
- 2015-01-07 CA CA2935880A patent/CA2935880A1/en not_active Abandoned
- 2015-01-07 AU AU2015205348A patent/AU2015205348A1/en not_active Abandoned
- 2015-01-07 EP EP15703102.2A patent/EP3092226B1/en not_active Revoked
- 2015-01-07 HK HK17105242.6A patent/HK1231480A1/zh unknown
- 2015-01-07 WO PCT/IB2015/050119 patent/WO2015104662A1/en not_active Ceased
- 2015-01-07 EA EA201691401A patent/EA201691401A1/ru unknown
- 2015-01-07 JP JP2016563277A patent/JP2017505337A/ja not_active Ceased
- 2015-01-07 BR BR112016015983A patent/BR112016015983A2/pt not_active Application Discontinuation
-
2016
- 2016-06-30 IL IL246555A patent/IL246555A0/en unknown
- 2016-07-05 PH PH12016501338A patent/PH12016501338A1/en unknown
- 2016-07-11 CU CUP2016000109A patent/CU20160109A7/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017505337A5 (https=) | ||
| JP2017502088A5 (https=) | ||
| ES2975436T3 (es) | Enantiómeros (R) y (S) de n-(5-(3-hidroxipirrolidin-1-il)-2-morfolinooxazolo[4,5-b]piridin-6-il)-2-(2-metilpiridin-4- il)oxazol-carboxamida como inhibidores de IRAK4 para el tratamiento del cáncer | |
| JP2017518348A5 (https=) | ||
| AU2008275891B2 (en) | 5-membered heterocyclic amides and related compounds | |
| JP2016531870A5 (https=) | ||
| JP2015528801A5 (https=) | ||
| IL303987A (en) | IRAK joints and their uses | |
| JP2015503618A5 (https=) | ||
| RU2016110852A (ru) | Ингибиторы irak и их применения | |
| RU2016140870A (ru) | Ингибиторы irak и их применения | |
| EA035499B1 (ru) | Новые ингибиторы глутаминазы | |
| JPWO2022147465A5 (https=) | ||
| BR112016011788B1 (pt) | Derivados de benzotriazol como moduladores de atividade de tnf | |
| CN112778336B (zh) | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 | |
| US11753418B2 (en) | Compounds for the modulation of Myc activity | |
| WO2016197078A1 (en) | Compounds for the modulation of myc activity | |
| AU2021373162B2 (en) | Pyrazolopyridazinone compound, and pharmaceutical composition and use thereof | |
| TW200951139A (en) | Chemical compounds 293 | |
| WO2025034951A1 (en) | Pharmaceutical compounds and compositions as c-kit kinase inhibitors | |
| CN112851668A (zh) | Atr抑制剂及其在医药上的应用 | |
| WO2021253095A1 (en) | Sulphonamide compounds | |
| AU2020346936A1 (en) | Novel tricyclic aromatic heterocyclic compound, preparation method therefor, pharmaceutical composition and application thereof | |
| IL282527B2 (en) | History and Use of 5-Azaindazole | |
| CN111303128B (zh) | 一种多环类化合物、其制备方法及应用 |